Jon Cuthbert - Author on Grafa
All
Palvella Therapeutics outlines robust 2026 roadmap for QTORIN platform
Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.



-640x358.jpg&w=1200&q=75)


-640x358.jpg&w=1200&q=75)



